 |
PDBsum entry 4gvj
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Hydrolase
|
|
|
Title:
|
|
Tyk2 (jh1) in complex with adenosine di-phosphate
|
|
Structure:
|
|
Non-receptor tyrosine-protein kinase tyk2. Chain: a. Fragment: kinase domain, unp residues 885-1176. Engineered: yes. Mutation: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Gene: tyk2. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Expression_system_cell_line: tni.
|
|
Resolution:
|
|
|
2.03Å
|
R-factor:
|
0.190
|
R-free:
|
0.231
|
|
|
Authors:
|
|
J.Liang,A.V.Abbema,L.Bao,K.Barrett,M.Beresini,L.Berezhkovskiy, W.Blair,C.Chang,J.Driscoll,C.Eigenbrot,N.Ghilardi,P.Gibbons, J.Halladay,A.Johnson,P.B.Kohli,Y.Lai,M.Liimatta,P.Mantik, K.Menghrajani,J.Murray,A.Sambrone,Y.Shao,S.Shia,Y.Shin,J.Smith, S.Sohn,M.Stanley,V.Tsui,M.Ultsch,L.Wu,B.Zhang,S.Magnuson
|
|
Key ref:
|
|
J.Liang
et al.
(2013).
Lead identification of novel and selective TYK2 inhibitors.
Eur J Med Chem,
67,
175-187.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
30-Aug-12
|
Release date:
|
14-Aug-13
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
P29597
(TYK2_HUMAN) -
Non-receptor tyrosine-protein kinase TYK2 from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
1187 a.a.
290 a.a.*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
*
PDB and UniProt seqs differ
at 7 residue positions (black
crosses)
|
|
|
|
|
|
|
|
|
|
|
|
|
Enzyme class:
|
|
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
|
|
|
|
|
Reaction:
|
|
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
|
|
|
|
|
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
Bound ligand (Het Group name = )
corresponds exactly
|
+
|
ADP
|
+
|
H(+)
|
|
|
|
|
|
|
|
|
|
|
|
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
| |
|
DOI no:
|
Eur J Med Chem
67:175-187
(2013)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Lead identification of novel and selective TYK2 inhibitors.
|
|
J.Liang,
V.Tsui,
A.Van Abbema,
L.Bao,
K.Barrett,
M.Beresini,
L.Berezhkovskiy,
W.S.Blair,
C.Chang,
J.Driscoll,
C.Eigenbrot,
N.Ghilardi,
P.Gibbons,
J.Halladay,
A.Johnson,
P.B.Kohli,
Y.Lai,
M.Liimatta,
P.Mantik,
K.Menghrajani,
J.Murray,
A.Sambrone,
Y.Xiao,
S.Shia,
Y.Shin,
J.Smith,
S.Sohn,
M.Stanley,
M.Ultsch,
B.Zhang,
L.C.Wu,
S.Magnuson.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Links
